Cross-cultural adaptation and validation of the Finnish version of the central sensitization inventory and its relationship with dizziness and postural control.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
31 Mar 2021
Historique:
received: 25 12 2020
accepted: 09 03 2021
entrez: 31 3 2021
pubmed: 1 4 2021
medline: 9 6 2021
Statut: epublish

Résumé

Central Sensitization (CS) involves dysfunction in neurophysiological mechanisms that increase neuronal responses to both noxious and non-noxious stimuli in the central nervous system. The Central Sensitization Inventory (CSI) is considered the leading patient-reported outcome measure for assessing CS-related symptoms. The aim of this study was to translate and cross-culturally adapt the CSI into Finnish (CSI-FI) and to evaluate its psychometric properties. Translation and cross-cultural validation of the CSI was conducted according to established guidelines. The validation sample was 229 subjects, including 42 pain free controls and 187 subjects with chronic musculoskeletal pain. The CSI-FI was evaluated for internal consistency, test-retest reliability, exploratory factor analysis with maximum likelihood extraction, relationship with subject-reported outcome measures [Tampa scale of kinesiophobia (TSK), the Depression scale (DEPS), 5-level EQ-5D version (EQ-5 L-5D), Roland-Morris Disability Questionnaire (RMDQ), and Pain and Sleep Questionnaire Three-Item Index (PSQ-3)], pain history, subjective symptoms of dizziness, and CS-related diagnoses on CSI part B. Furthermore, we studied the ability of the CSI-FI to distinguish pain free controls, subjects with chronic pain in a single body area, and subjects with multisite chronic pain. In addition, we studied the relationship of CSI-FI scores with postural control on a force plate. The CSI-FI demonstrated good internal consistency (0.884) and excellent test-retest reliability (0.933) with a 7 ± 1 day gap between test administrations. Exploratory factor analysis with maximum likelihood extraction yielded a one factor solution. Fair to good correlations were found between the CSI-FI and the TSK, DEPS, EQ-5 L-5D, RMDQ, and PSQ-3. Subjective symptoms of dizziness correlated better with CSI-FI scores than any of the CS-related diagnoses on CSI part B. Total CSI-FI scores successfully distinguished between pain free controls, subjects with chronic pain in a single body area, and subjects with multisite chronic pain. The multisite pain group reported significantly more dizziness symptoms than the other two groups. Force plate measurements showed no relationship between postural control and CSI-FI scores. The CSI-FI translation was successfully cross-culturally adapted and validated into Finnish. CSI-FI psychometric properties and scores were all in acceptable levels and in line with previous CSI validations. The CSI-FI appears to be a valid and reliable instrument for assessing CS-related symptomology in Finnish-speaking populations.

Sections du résumé

BACKGROUND BACKGROUND
Central Sensitization (CS) involves dysfunction in neurophysiological mechanisms that increase neuronal responses to both noxious and non-noxious stimuli in the central nervous system. The Central Sensitization Inventory (CSI) is considered the leading patient-reported outcome measure for assessing CS-related symptoms. The aim of this study was to translate and cross-culturally adapt the CSI into Finnish (CSI-FI) and to evaluate its psychometric properties.
METHODS METHODS
Translation and cross-cultural validation of the CSI was conducted according to established guidelines. The validation sample was 229 subjects, including 42 pain free controls and 187 subjects with chronic musculoskeletal pain. The CSI-FI was evaluated for internal consistency, test-retest reliability, exploratory factor analysis with maximum likelihood extraction, relationship with subject-reported outcome measures [Tampa scale of kinesiophobia (TSK), the Depression scale (DEPS), 5-level EQ-5D version (EQ-5 L-5D), Roland-Morris Disability Questionnaire (RMDQ), and Pain and Sleep Questionnaire Three-Item Index (PSQ-3)], pain history, subjective symptoms of dizziness, and CS-related diagnoses on CSI part B. Furthermore, we studied the ability of the CSI-FI to distinguish pain free controls, subjects with chronic pain in a single body area, and subjects with multisite chronic pain. In addition, we studied the relationship of CSI-FI scores with postural control on a force plate.
RESULTS RESULTS
The CSI-FI demonstrated good internal consistency (0.884) and excellent test-retest reliability (0.933) with a 7 ± 1 day gap between test administrations. Exploratory factor analysis with maximum likelihood extraction yielded a one factor solution. Fair to good correlations were found between the CSI-FI and the TSK, DEPS, EQ-5 L-5D, RMDQ, and PSQ-3. Subjective symptoms of dizziness correlated better with CSI-FI scores than any of the CS-related diagnoses on CSI part B. Total CSI-FI scores successfully distinguished between pain free controls, subjects with chronic pain in a single body area, and subjects with multisite chronic pain. The multisite pain group reported significantly more dizziness symptoms than the other two groups. Force plate measurements showed no relationship between postural control and CSI-FI scores.
CONCLUSION CONCLUSIONS
The CSI-FI translation was successfully cross-culturally adapted and validated into Finnish. CSI-FI psychometric properties and scores were all in acceptable levels and in line with previous CSI validations. The CSI-FI appears to be a valid and reliable instrument for assessing CS-related symptomology in Finnish-speaking populations.

Identifiants

pubmed: 33784969
doi: 10.1186/s12883-021-02151-6
pii: 10.1186/s12883-021-02151-6
pmc: PMC8011151
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

141

Références

J Pain. 2009 Sep;10(9):895-926
pubmed: 19712899
J Rehabil Med. 2015 Mar;47(3):249-55
pubmed: 25483309
PLoS One. 2018 May 3;13(5):e0196575
pubmed: 29723223
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
Eur Spine J. 2011 Mar;20(3):358-68
pubmed: 20721676
Pain Pract. 2018 Apr;18(4):463-472
pubmed: 28777895
Int J Environ Res Public Health. 2020 May 01;17(9):
pubmed: 32370043
Pain. 2011 Mar;152(3 Suppl):S2-S15
pubmed: 20961685
Disabil Rehabil. 2019 Jun;41(13):1514-1523
pubmed: 29382241
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3115-24
pubmed: 11124727
Med Care. 2007 May;45(5 Suppl 1):S22-31
pubmed: 17443115
J Physiother. 2016 Apr;62(2):116
pubmed: 26687949
BMC Neurol. 2020 Jul 27;20(1):286
pubmed: 32718330
Nat Rev Neurol. 2018 Mar;14(3):183-189
pubmed: 29377011
Gerontology. 2017;63(1):67-83
pubmed: 27172932
Pain Pract. 2020 Sep;20(7):724-736
pubmed: 32285543
Br J Anaesth. 2008 Jul;101(1):17-24
pubmed: 18487245
J Back Musculoskelet Rehabil. 2021;34(2):261-267
pubmed: 33285622
Pain Physician. 2015 May-Jun;18(3):E333-46
pubmed: 26000680
Front Neurosci. 2018 Mar 20;12:171
pubmed: 29615859
J Autism Dev Disord. 2010 Jan;40(1):8-20
pubmed: 19609833
Clin J Pain. 2016 Jul;32(7):624-30
pubmed: 26418360
Springerplus. 2016 Oct 21;5(1):1837
pubmed: 27818875
Eur Spine J. 2006 Jan;15 Suppl 1:S17-24
pubmed: 16320034
Pain Med. 2020 Nov 1;21(11):2958-2963
pubmed: 32232473
Gait Posture. 2016 Feb;44:1-6
pubmed: 27004624
Pain Res Manag. 2012 Jul-Aug;17(4):281-90
pubmed: 22891194
Pain Pract. 2020 Jun;20(5):480-490
pubmed: 32022985
Pain Pract. 2012 Apr;12(4):276-85
pubmed: 21951710
Fam Pract. 2010 Oct;27(5):527-34
pubmed: 20554653
Arthritis Rheum. 2009 Sep;60(9):2839-44
pubmed: 19714636
Scand J Rehabil Med. 1996 Dec;28(4):225-32
pubmed: 9122651
J Clin Rheumatol. 2009 Feb;15(1):16-21
pubmed: 19125137
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
Am J Med. 2017 Dec;130(12):1465.e1-1465.e9
pubmed: 28739195
PLoS One. 2017 Dec 7;12(12):e0188719
pubmed: 29216211
J Pain. 2018 Mar;19(3):317-329
pubmed: 29198933
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
J Pain. 2016 Oct;17(10):1058-1067
pubmed: 27369186
Pain Pract. 2018 Apr;18(4):544-554
pubmed: 28851012
Pain Pract. 2017 Feb;17(2):166-175
pubmed: 26989894
Semin Arthritis Rheum. 2007 Jun;36(6):339-56
pubmed: 17350675
Musculoskelet Sci Pract. 2018 Oct;37:20-28
pubmed: 29966856
BMC Med Res Methodol. 2010 Mar 18;10:22
pubmed: 20298572
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(6):51-56
pubmed: 32678548
BMC Musculoskelet Disord. 2007 Mar 09;8:27
pubmed: 17349056
Gait Posture. 2010 Oct;32(4):436-45
pubmed: 20947353
Lancet. 2018 Jun 9;391(10137):2356-2367
pubmed: 29573870
Pain Pract. 2020 Feb;20(2):188-196
pubmed: 31605651
J Am Med Dir Assoc. 2020 May;21(5):597-603.e8
pubmed: 32334772
Am J Med. 2018 Dec;131(12):1431-1437
pubmed: 29859806
J Pain. 2013 May;14(5):438-45
pubmed: 23490634
J Pain Res. 2017 Sep 01;10:2109-2122
pubmed: 28979158

Auteurs

Jani Mikkonen (J)

Private practice, Helsinki, Finland. jani@selkakuntoutus.fi.
Department of Surgery (incl. Physiatry), Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. jani@selkakuntoutus.fi.

Hannu Luomajoki (H)

ZHAW School of Health Professions, Winterthur, Switzerland.

Olavi Airaksinen (O)

Department of Surgery (incl. Physiatry), Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Department of Physical and Rehabilitation Medicine, Kuopio University Hospital, Kuopio, Finland.

Randy Neblett (R)

PRIDE Research Foundation, Dallas, TX, USA.

Tuomas Selander (T)

Science Service Center, Kuopio University Hospital, Kuopio, Finland.

Ville Leinonen (V)

Institute of Clinical Medicine-Neurosurgery, University of Eastern Finland, Kuopio, Finland.
Department of Neurosurgery, Kuopio University Hospital, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH